Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786904 | 0.82 | MCL1 (0.46) | MCL1CHEK1FLT3USP7LMNA | |
| SCHEMBL9387631 | 0.81 | TLR7 (0.61) | TLR7LMNA | |
| Water SCHEMBL10743629 | 0.80 | TLR7 (0.60) | TLR7LMNA | |
| SCHEMBL3868134 | 0.80 | TLR7 (0.48) | TLR7CHEK1FLT3EGLN1 | |
| SCHEMBL3867965 | 0.79 | TLR7 (0.42) | TLR7MCL1USP7LMNAPTGES | |
| SCHEMBL4531190 | 0.78 | TLR7 (0.71) | TLR7LMNAPTGES | |
| SCHEMBL29463859 | 0.78 | NPC1 (0.44) | TLR7MCL1LMNA | |
| SCHEMBL12144994 | 0.78 | NPC1 (0.44) | TLR7MCL1LMNA | |
| SCHEMBL1486542 | 0.77 | TLR7 (0.46) | TLR7 | |
| SCHEMBL3862141 | 0.76 | TLR7 (0.45) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| EP-1845988-A2 | SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006091394-A2 | SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | TLR7 35/4885MCL1 288/4885CHEK1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.